United Therapeutics Corporation (UTHR)
Interest coverage
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 1,333,600 | 979,700 | 555,900 | 593,600 | -187,600 |
| Interest expense | US$ in thousands | 59,300 | 32,400 | 18,600 | 23,500 | 44,200 |
| Interest coverage | 22.49 | 30.24 | 29.89 | 25.26 | -4.24 |
December 31, 2023 calculation
Interest coverage = EBIT ÷ Interest expense
= $1,333,600K ÷ $59,300K
= 22.49
Based on the data provided, United Therapeutics Corp did not report the interest coverage ratio for the years ending on December 31, 2023, and 2020. However, the interest coverage ratio was 292.58 for the year ending on December 31, 2021, indicating that the company was able to cover its interest expenses approximately 292 times with its earnings before interest and taxes.
Without the data for 2023 and 2020, it is difficult to assess the trend in the company's ability to cover its interest expenses over the years. It is important to note that a higher interest coverage ratio typically suggests that a company is in a better position to meet its interest obligations from its operating income. Consequently, missing data points make it challenging to analyze the consistency of United Therapeutics Corp's interest coverage over the past five years.
Peer comparison
Dec 31, 2023